secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001193125-24-234814
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase posts new corporate presentation highlighting PAH clinical program
-----------------------------------------------------------------------------

- New company presentation made available on investor relations website October 9, 2024.
- Presentation focuses on clinical development of disease-modifying therapeutics for pulmonary arterial hypertension (PAH).
- No specific financial results, trial data, or guidance disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/0001193125-24-234814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/d882180d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-234814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer